.png)
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni close a $27M oversubscribed Series A round, appoint new executives, announce regulatory milestones, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Appointed Janet Kube as its new Chief Executive Officer. 1MED is a Swiss-based global end-to-end development consultancy specializing in medical devices, novel technologies, and combination product fields.
Appointed LSI Alumni Todd Usen as Chief Executive Officer and Director, succeeding founder Olav Bergheim, who will serve as an advisor. The company also appointed Orly Mishan as its new Chairperson of the Board of Directors.
Announced that its dual-chamber infusion system was accepted in the U.S. FDA’s Safer Technologies Program (STeP). This milestone will support Altra’s upcoming 510(k) submission, bringing its advanced infusion system with air-in-line and occlusion detection closer to commercialization.
Closed a $27M oversubscribed Series A equity financing round co-led by Amplitude Ventures and an undisclosed strategic partner. The funds will be used to further validate the company’s ReSolv stent, a bioabsorbable polymer-based stent for brain aneurysms.
Appointed Chris Toth as an independent board member to support its commercial acceleration. Toth’s extensive experience in managing and scaling commercial operations is anticipated to enhance the company’s strategic initiatives.
Appointed LSI Alumni Todd Usen as Chair of the Board, succeeding Dr. Volker Pfahlert. Usen’s leadership is expected to guide NeoPredics in advancing predictive analytics for maternal and neonatal healthcare.
Announced a strategic partnership with Neuronostics. By combining Neuroelectrics’ EEG hardware with Neuronostics’ BioEP tool, the collaboration aims to enhance cohort identification and streamline clinical trial protocols.
Secured FDA approval to broaden its clinical trial for TETRANITE, its proprietary bone adhesive biomaterial. The company also earned reimbursement coverage from the CMS for TETRANITE’s application as a replacement for traditional metal plates and screws.
Announced positive results from two studies demonstrating that its Clotild Smart Guidewire System can successfully identify “fresh” clots in peripheral artery disease (PAD). The data from the SEPARATE and E-SEPARATE studies were presented at the Paris Vascular Insights Course.
Completed its Series B funding round, securing a final tranche of Can$5.3M. The funds will support regulatory submissions, product commercialization, and ongoing development of its minimally invasive Triojection therapy, designed to treat contained herniated discs.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
